IL111721A - Isoxazolines and isoxazoles and pharmaceutical compositions containing them - Google Patents

Isoxazolines and isoxazoles and pharmaceutical compositions containing them

Info

Publication number
IL111721A
IL111721A IL11172194A IL11172194A IL111721A IL 111721 A IL111721 A IL 111721A IL 11172194 A IL11172194 A IL 11172194A IL 11172194 A IL11172194 A IL 11172194A IL 111721 A IL111721 A IL 111721A
Authority
IL
Israel
Prior art keywords
isoxazoles
pharmaceutical compositions
compositions containing
isoxazolines
compounds
Prior art date
Application number
IL11172194A
Other languages
English (en)
Other versions
IL111721A0 (en
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL111721A0 publication Critical patent/IL111721A0/xx
Publication of IL111721A publication Critical patent/IL111721A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11172194A 1993-11-24 1994-11-21 Isoxazolines and isoxazoles and pharmaceutical compositions containing them IL111721A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15759893A 1993-11-24 1993-11-24
US23296194A 1994-04-22 1994-04-22
US33792094A 1994-11-10 1994-11-10

Publications (2)

Publication Number Publication Date
IL111721A0 IL111721A0 (en) 1995-01-24
IL111721A true IL111721A (en) 2000-06-01

Family

ID=27388036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11172194A IL111721A (en) 1993-11-24 1994-11-21 Isoxazolines and isoxazoles and pharmaceutical compositions containing them

Country Status (24)

Country Link
EP (2) EP0970950A3 (fr)
JP (1) JPH09505590A (fr)
KR (1) KR100359046B1 (fr)
AT (1) ATE198748T1 (fr)
AU (1) AU695853B2 (fr)
BR (1) BR9408137A (fr)
CA (1) CA2174838A1 (fr)
CZ (1) CZ141996A3 (fr)
DE (1) DE69426604T2 (fr)
DK (1) DK0730590T3 (fr)
ES (1) ES2154326T3 (fr)
FI (1) FI962184A (fr)
GR (1) GR3035610T3 (fr)
HR (1) HRP940952A2 (fr)
HU (1) HUT74690A (fr)
IL (1) IL111721A (fr)
NO (1) NO309768B1 (fr)
NZ (1) NZ276633A (fr)
PL (1) PL182303B1 (fr)
PT (1) PT730590E (fr)
RU (1) RU2149871C1 (fr)
SK (1) SK66696A3 (fr)
TW (1) TW483895B (fr)
WO (1) WO1995014683A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU713235B2 (en) 1995-09-29 1999-11-25 Cor Therapeutics, Inc. Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
EP0858457A1 (fr) * 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH Heterocycles a 5 chainons, medicaments contenant ces composes, utilisation et procede de production correspondants
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
ATE267011T1 (de) * 1995-12-21 2004-06-15 Bristol Myers Squibb Pharma Co Isoxazolin, isothiazolin und pyrazolin als faktor xa inhibitoren
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU1345697A (en) * 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
WO1997033887A1 (fr) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Inhibiteurs de l'integrine spirocycle
WO1997048395A1 (fr) * 1996-06-19 1997-12-24 Du Pont Pharmaceuticals Company Administration iontophoretique d'inhibiteurs de l'integrine
AU3970697A (en) * 1996-08-15 1998-03-06 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
US5900414A (en) * 1996-08-29 1999-05-04 Merck & Co., Inc. Methods for administering integrin receptor antagonists
WO1998008840A1 (fr) * 1996-08-29 1998-03-05 Merck & Co., Inc. Antagonistes de l'integrine
US5797867A (en) 1996-09-27 1998-08-25 Becton Dickinson And Company Iontophoretic drug delivery system, including method for activating same for attachment to patient
US5738647A (en) 1996-09-27 1998-04-14 Becton Dickinson And Company User activated iontophoretic device and method for activating same
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
US6022977A (en) * 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
US6100260A (en) * 1997-04-21 2000-08-08 Sumitomo Pharmaceutical Company, Limited Isoxazole derivatives
HRP980291A2 (en) 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
PL337831A1 (en) * 1997-06-19 2000-09-11 Du Pont Pharm Co Inhibitors of factor xa containing a specificity giving p1 group
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
ZA988735B (en) 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
US6136833A (en) * 1998-01-16 2000-10-24 Dupont Pharmaceuticals Company Pharmaceutical formulations and process for their preparation
WO1999050255A2 (fr) 1998-03-27 1999-10-07 Du Pont Pharmaceuticals Company Pyrazolines et triazolines disubstituees, utilisees en tant qu'inhibiteurs du facteur xa
WO2000000481A1 (fr) * 1998-06-29 2000-01-06 Du Pont Pharmaceuticals Company Isoxazolidines et carbamates cycliques utilises comme antagonistes de iib/iiia
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
EP1131306A2 (fr) 1998-11-18 2001-09-12 Du Pont Pharmaceuticals Company Antagonistes du recepteur de fibrinogene a base d'isoxazoline
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
WO2000053168A2 (fr) * 1999-03-11 2000-09-14 Du Pont Pharmaceuticals Company Synergie entre l'heparine a faible masse moleculaire et des inhibiteurs d'agregation plaquettaire permettant d'elaborer une polytherapie pour la prevention et le traitement de divers troubles thromboemboliques
AU766089B2 (en) * 1999-03-11 2003-10-09 Du Pont Pharmaceuticals Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin
ES2197092T3 (es) 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
UA81235C2 (en) 2001-11-26 2007-12-25 Genentech Inc Catheter composition and uses thereof
US7759387B2 (en) 2003-10-08 2010-07-20 Piramal Life Sciences Limited Fibrinogen receptor antagonists and their use
CA2558848C (fr) 2004-03-05 2013-11-19 Nissan Chemical Industries, Ltd. Compose de benzamide a substitution isoxazoline et pesticide
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
NZ552183A (en) 2004-06-17 2009-10-30 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7414134B2 (en) 2004-10-12 2008-08-19 Amgen Inc. B1 bradykinin receptor antagonists
JP2008515976A (ja) 2004-10-13 2008-05-15 アムジエン・インコーポレーテツド トリアゾール及びブラジキニンｂ１受容体拮抗物質としてのその使用
BRPI0617076B1 (pt) 2005-09-02 2021-07-06 Nissan Chemical Corporation Composto benzamida substituída por isoxazolina da fórmula (1) ou sal do mesmo; composto benzamida substituido por 4-hidroxiiminametila da fórmula (2) ou sal do mesmo; pesticida; agente agroquímico; parasiticida interno ou externo para mamíferos ou aves; inseticida ou acaricida
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
CN103265495B (zh) 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US8916148B2 (en) 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
TW201040166A (en) 2009-04-07 2010-11-16 Astrazeneca Ab Isoxazol-3(2H)-one analogs as therapeutic agents
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CN105636953B (zh) 2013-07-31 2018-01-02 诺华股份有限公司 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
AR114489A1 (es) * 2018-04-12 2020-09-09 Morphic Therapeutic Inc ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
WO1992019595A1 (fr) * 1991-05-07 1992-11-12 Merck & Co., Inc. Antagonistes de recepteur de fibrinogene
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JP3240534B2 (ja) * 1992-06-05 2001-12-17 コニカ株式会社 画像形成方法

Also Published As

Publication number Publication date
HUT74690A (en) 1997-01-28
TW483895B (en) 2002-04-21
SK66696A3 (en) 1996-11-06
DE69426604T2 (de) 2001-05-10
ES2154326T3 (es) 2001-04-01
BR9408137A (pt) 1997-08-12
WO1995014683A1 (fr) 1995-06-01
NO962096L (no) 1996-05-23
EP0970950A2 (fr) 2000-01-12
FI962184A0 (fi) 1996-05-23
ATE198748T1 (de) 2001-02-15
HRP940952A2 (en) 1997-04-30
EP0730590A1 (fr) 1996-09-11
NO309768B1 (no) 2001-03-26
NO962096D0 (no) 1996-05-23
JPH09505590A (ja) 1997-06-03
GR3035610T3 (en) 2001-06-29
CZ141996A3 (en) 1996-11-13
DK0730590T3 (da) 2001-03-19
KR100359046B1 (ko) 2003-08-02
HU9601414D0 (en) 1996-07-29
NZ276633A (en) 1998-04-27
IL111721A0 (en) 1995-01-24
EP0730590B1 (fr) 2001-01-17
DE69426604D1 (de) 2001-02-22
KR960705794A (ko) 1996-11-08
AU695853B2 (en) 1998-08-27
FI962184A (fi) 1996-05-23
PT730590E (pt) 2001-05-31
PL314591A1 (en) 1996-09-16
CA2174838A1 (fr) 1995-06-01
AU1098095A (en) 1995-06-13
RU2149871C1 (ru) 2000-05-27
PL182303B1 (en) 2001-12-31
EP0970950A3 (fr) 2000-04-05

Similar Documents

Publication Publication Date Title
IL111721A (en) Isoxazolines and isoxazoles and pharmaceutical compositions containing them
IL118262A0 (en) Isoxazolines and pharmaceutical compositions containing them
DK0730589T3 (da) Isoxazolinforbindelser, der er nyttige som fibrinogenreceptorantagonister
IL99537A0 (en) Fibrinogen receptor antagonists and pharmaceutical compositions containing them
HUT62337A (en) New cyclosporins, pharmaceutical compositions comprising such compounds and process for producing same
MX9203050A (es) Compuestos de analogos de triptamina.
IL103252A0 (en) Cyclic compounds and pharmaceutical compositions containing them
DK58291D0 (da) Krystalinsk stof og dets fremstilling
WO2005035495A3 (fr) Antagonistes du recepteur du fibrinogene et leur utilisation
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
MX9709081A (es) Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
GB9412548D0 (en) Chemical compounds
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it
GB9116056D0 (en) Compounds
ZA917369B (en) Calcium uptake inhibitors
BR9809742A (pt) Roxifiban cristalino, composição farmacêutica, método para inibir a aglutinação de uma proteìna, método para tratamento ou prevenção e distúrbios tromboembólicos e método para inibir a aglutinação de uma proteìna

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed